MII

Name

MII

Legal name

MII

Website

https://miiscience.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Dermatology R&D and Venture Capital

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industry

Psoriasis & Eczema Specialty Care (HLAKACAL)

Keywords

• Dermatology venture capital
• Topical drug development
• Skincare R&D services
• Life sciences investment
• Clinical proof of concept

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Venture Capital Investment Returns: Mii Fund invests in dermatology-related technologies from seed to growth stage. Generates returns through equity appreciation, exits via IPOs or acquisitions of portfolio companies.
2. R&D Lab Services: MiiLabs provides dermatology excellence center services including proof of concept development, formulation, and clinical study support for skin-related innovations.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

MII operates a vertically integrated Fund+Lab model for dermatology innovation. Mii Fund provides venture capital investment to skin-related technologies across seed to growth stages covering pharma, biotech, medical device, digital health, and cosmetics. Mii Labs, headquartered in Rehovot, Israel, provides R&D services advancing dermatology innovations from concept to clinical proof of concept, with expertise in topical drug development. The two arms together create a holistic ecosystem bringing R&D, venture capital, and strategic partnerships under one roof.

Product overview

MII operates a vertically integrated Fund+Lab model for dermatology innovation. The core offering consists of Mii Fund, a venture capital fund investing in skin-related technologies across all stages from seed to growth, and Mii Labs, a state-of-the-art dermatology excellence center in Rehovot, Israel that advances innovations from concept to clinical proof of concept. Together with three portfolio companies—Seanergy Pharma (topical therapeutics for inflammatory skin conditions), Follicle Pharma (hair follicle delivery systems), and Noon Aesthetics (skin care products with DermShield technology)—the ecosystem provides end-to-end coverage from R&D to market for dermatological and skin-care innovations.

Differentiator

Problem solved

Functional benefit

Brands

• MiiLabs: State-of-the-art dermatology excellence center in Rehovot, Israel, focused on taking ideas to proof of concept and clinical development.
• MiiFund
• MiiWin

Products and services

• Mii Fund Venture capital fund investing in dermatology and skin care innovations from seed to growth stage, covering pharma, biotech, medical device, digital health, and cosmetic sectors. Provides smart capital, go-to-market experience, global derma-network access, and privileged entry into the Japanese market through the Maruho partnership. Targeted at innovators and founders of skin-related technologies.
• Mii Labs Dermatology excellence center headquartered in Rehovot, Israel, adjacent to the Weizmann Institute. Advances dermatology and skin care innovations from inception to clinical proof of concept. Provides expertise in topical drug development with active ingredients including poorly soluble compounds, new chemical entities (NCEs), small and large molecules, pro-drugs, and high potency compounds. Targeted at scientists, clinicians, entrepreneurs, and big pharma partners seeking dermatology R&D support.

Quantifiable outcome

• From concept to clinical proof of concept in the shortest, most effective and lean way
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Weizmann Institute of ScienceminorStrategic or Co-development PartnerMii Labs is located adjacent to the Weizmann Institute in Rehovot, Israel's life science capital. This proximity enables collaboration with world-class researchers and access to cutting-edge scientific expertise in the bio-research ecosystem.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• BridgeBio Pharma: Hybrid clinical-stage biotech and asset-incubator model that builds multiple therapeutic franchises simultaneously. Conceptually similar in operating a portfolio of development programs under a centralized R&D umbrella, though focused on genetic disease rather than dermatology.
• Arcutis Biotherapeutics: US-based late clinical-stage dermatology biotech focused on topical treatments for inflammatory skin diseases including atopic dermatitis and psoriasis — the same therapeutic categories pursued by MII portfolio company Seanergy Pharma and the Mii Labs topical platform.
• Dermavant Sciences: Specialty dermatology biotech developing topical therapies for inflammatory skin diseases. Directly comparable product strategy and target indications, representing the kind of independent derm-focused commercial company MII's fund aims to build or partner with.
• Tarsus Pharmaceuticals: Dermatology-adjacent specialty pharma focused on therapeutic areas underserved by large incumbents. Comparable as a developer of innovative topical/dermatology products targeting niche indications — representative of the type of company MII seeks to incubate or invest in.

Broad incumbents

• Galderma: Global dermatology-focused pharmaceutical company spanning prescription, aesthetics, and consumer skin care. Comparable as the largest pure-play dermatology commercial platform globally and the natural exit/acquirer candidate for MII portfolio assets.
• Maruho: Japan's leading dermatology pharmaceutical company and MII's parent/strategic partner. Directly comparable dermatology focus and topical drug franchise; operates at substantially larger scale as a fully integrated specialty pharma versus MII's fund+lab developer role.

Direct peers

• Apollo Therapeutics: A UK-based fund+lab hybrid that pairs venture capital with pharma R&D capabilities from AstraZeneca, GSK, and Johnson & Johnson. Most structurally comparable to MII in combining drug-discovery infrastructure with dedicated capital, though operating at larger scale and across multiple therapy areas rather than dermatology only.

Others

• Frazier Healthcare Partners: US healthcare-focused private equity and venture firm with deep dermatology and specialty pharma track record. Most comparable US analog as a dermatology-active life-sciences investor, though structured as a traditional fund rather than the integrated lab model.
• OrbiMed: One of the largest dedicated healthcare investment firms globally, with significant dermatology and specialty pharma exposure across stages. Comparable as a healthcare-focused venture investor, but far larger, more diversified, and lacking an in-house development lab.

Regional players

• Arkin Holdings: Israeli life-sciences investment firm holding significant dermatology and specialty pharma positions. Most relevant Israeli regional peer as a local VC with overlapping interest in dermatology innovation and access to the Weizmann ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MII